Making Money
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
GEPT- Look at their customer list.
http://airworksinc.com/airworks/customer.html
Domestic Airlines
Alaska Airlines, Aloha Airlines, American Airlines, American Eagle Airlines, America West, Continental Airlines, Delta Airlines, Executive Airlines, Frontier Airlines, Legend Airlines, Midwest Express, Northwest Airlines, Sun Country Airlines, Southwest Airlines, Transmeridian Airlines, United Airlines, U.S. Airways, USA 3000
International Airlines
Air Berlin, Air Canada, Air China, Air Greenland, Air Macau, Air One, Aero Bolivia, Aero Lloyd, Britannia, Blue Wings, Cathay Pacific, China Eastern Airlines, China Southern Airlines, China Xinjiang Airlines, City Bird, Condor, Condor Berlin, Condor Cargo, Croatia Airlines, Dragon Air, Emirates, Finnair, First Choice (Air 2000), GE Capital Aviation, German Wings, Iberia, JMC Manchester, KLM, Kuwait Airline, Lan Chile, Lufthansa Airlines, Lufthansa Cityline, Lufthansa Technik, LTU, Meridiana, Qatar, Airlines, SAS, Saudi Royal Fleet, Singapore Airlines, SR Technics, Swiss Air International, Thomas Cook, Varig, Virgin Atlantic
GEPT- Look at their customer list.
http://airworksinc.com/airworks/customer.html
Domestic Airlines
Alaska Airlines, Aloha Airlines, American Airlines, American Eagle Airlines, America West, Continental Airlines, Delta Airlines, Executive Airlines, Frontier Airlines, Legend Airlines, Midwest Express, Northwest Airlines, Sun Country Airlines, Southwest Airlines, Transmeridian Airlines, United Airlines, U.S. Airways, USA 3000
International Airlines
Air Berlin, Air Canada, Air China, Air Greenland, Air Macau, Air One, Aero Bolivia, Aero Lloyd, Britannia, Blue Wings, Cathay Pacific, China Eastern Airlines, China Southern Airlines, China Xinjiang Airlines, City Bird, Condor, Condor Berlin, Condor Cargo, Croatia Airlines, Dragon Air, Emirates, Finnair, First Choice (Air 2000), GE Capital Aviation, German Wings, Iberia, JMC Manchester, KLM, Kuwait Airline, Lan Chile, Lufthansa Airlines, Lufthansa Cityline, Lufthansa Technik, LTU, Meridiana, Qatar, Airlines, SAS, Saudi Royal Fleet, Singapore Airlines, SR Technics, Swiss Air International, Thomas Cook, Varig, Virgin Atlantic
GEPT looks like it could be a monster.
GEPT looks like it could be a monster.
Sounds good to me!
Love watching ETMM and NITE jockey for shares.
GEPT monster runner DD post
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=61971003
GEPT monster runner DD post
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=61971003
Anybody called Ramon lately?
GEPT / BMOD. Safe plays that should grow with time. IMO.
GEPT is running bigly today! Woohoo. When is the dime break coming?
Bout time GEPT got discovered.
Liking what I see here!
Its just weird cause just by looking at the trades I'd say only 800k to 1m were sold. Wasn't a "ton" of selling, just no bid support.
VSHC bouncing big off the shake.
VSHC bouncing big off the shake.
8's on deck lol.
MM's just trying to shake loose a few shares. Sad that some folks fell for it.
She'll be thin going up.
VSHC ready to go!
RENO, Nev., April 12, 2011 /PRNewswire/ -- Visual Healthcare Corp. (the "Company") (NASDAQ OTC:VSHC.ob - News) announces today that work has begun on a Chinese based adaptation of the information technology grid that its clients use in their clinical trial applications.
This project has been launched in response to requests from both Chinese academic centers as well as Clinical Research Organization experts responding to Chinese government resolve to create a major domestic drug industry.
In 2007, the Chinese government had enacted a series of laws designed to create significant incentives in order to foster a fast-growth environment for the creation of a large scale pharmaceutical sector. While actual drug manufacturing has been growing, the complexities of running clinical trials according to Western standards has proved a more difficult challenge.
Many U.S. based CROs intend to support Chinese efforts as they see benefits from these developments such as the potential for off shore clinical trials at much lower cost. China may prove to be fertile ground for clinical trials with its large population which may ease hurdles ranging from cost, patient recruitment delays, patient compliance during participation, qualified professionals, new clinical trial patients, and other problems.
"Operating pharmaceutical testing facilities and clinical trials in China will require compatible software to manage their information gathering and data mining procedures," says Chairman Gerard Dab. "Yes it is a new market and it has some challenges such as conveying novel notions like informed consent but we believe that we can leverage our Chinese experience to generate significant business in helping this budding Chinese industry."
Although health is provincial or local, the central government now allocates special budgets to hospitals for acquisition of new technology, a move that will help usher in modern clinical trials. Another critical success factor may be our proven ability to secure active support from leading academic communities, vital for both best-practice and scientific credibility.
VSHC Huge news just out!!!
RENO, Nev., April 12, 2011 /PRNewswire/ -- Visual Healthcare Corp. (the "Company") (NASDAQ OTC:VSHC.ob - News) announces today that work has begun on a Chinese based adaptation of the information technology grid that its clients use in their clinical trial applications.
This project has been launched in response to requests from both Chinese academic centers as well as Clinical Research Organization experts responding to Chinese government resolve to create a major domestic drug industry.
In 2007, the Chinese government had enacted a series of laws designed to create significant incentives in order to foster a fast-growth environment for the creation of a large scale pharmaceutical sector. While actual drug manufacturing has been growing, the complexities of running clinical trials according to Western standards has proved a more difficult challenge.
Many U.S. based CROs intend to support Chinese efforts as they see benefits from these developments such as the potential for off shore clinical trials at much lower cost. China may prove to be fertile ground for clinical trials with its large population which may ease hurdles ranging from cost, patient recruitment delays, patient compliance during participation, qualified professionals, new clinical trial patients, and other problems.
"Operating pharmaceutical testing facilities and clinical trials in China will require compatible software to manage their information gathering and data mining procedures," says Chairman Gerard Dab. "Yes it is a new market and it has some challenges such as conveying novel notions like informed consent but we believe that we can leverage our Chinese experience to generate significant business in helping this budding Chinese industry."
Although health is provincial or local, the central government now allocates special budgets to hospitals for acquisition of new technology, a move that will help usher in modern clinical trials. Another critical success factor may be our proven ability to secure active support from leading academic communities, vital for both best-practice and scientific credibility.
VSHC Huge news just out!!!
RENO, Nev., April 12, 2011 /PRNewswire/ -- Visual Healthcare Corp. (the "Company") (NASDAQ OTC:VSHC.ob - News) announces today that work has begun on a Chinese based adaptation of the information technology grid that its clients use in their clinical trial applications.
This project has been launched in response to requests from both Chinese academic centers as well as Clinical Research Organization experts responding to Chinese government resolve to create a major domestic drug industry.
In 2007, the Chinese government had enacted a series of laws designed to create significant incentives in order to foster a fast-growth environment for the creation of a large scale pharmaceutical sector. While actual drug manufacturing has been growing, the complexities of running clinical trials according to Western standards has proved a more difficult challenge.
Many U.S. based CROs intend to support Chinese efforts as they see benefits from these developments such as the potential for off shore clinical trials at much lower cost. China may prove to be fertile ground for clinical trials with its large population which may ease hurdles ranging from cost, patient recruitment delays, patient compliance during participation, qualified professionals, new clinical trial patients, and other problems.
"Operating pharmaceutical testing facilities and clinical trials in China will require compatible software to manage their information gathering and data mining procedures," says Chairman Gerard Dab. "Yes it is a new market and it has some challenges such as conveying novel notions like informed consent but we believe that we can leverage our Chinese experience to generate significant business in helping this budding Chinese industry."
Although health is provincial or local, the central government now allocates special budgets to hospitals for acquisition of new technology, a move that will help usher in modern clinical trials. Another critical success factor may be our proven ability to secure active support from leading academic communities, vital for both best-practice and scientific credibility.
5,000 shares and the ask increases to .0085 lol. This is going over a penny today.
Just dropped 10 mins ago.
VSHC News 4/15/11
RENO, Nev., April 12, 2011 /PRNewswire/ -- Visual Healthcare Corp. (the "Company") (NASDAQ OTC:VSHC.ob - News) announces today that work has begun on a Chinese based adaptation of the information technology grid that its clients use in their clinical trial applications.
This project has been launched in response to requests from both Chinese academic centers as well as Clinical Research Organization experts responding to Chinese government resolve to create a major domestic drug industry.
In 2007, the Chinese government had enacted a series of laws designed to create significant incentives in order to foster a fast-growth environment for the creation of a large scale pharmaceutical sector. While actual drug manufacturing has been growing, the complexities of running clinical trials according to Western standards has proved a more difficult challenge.
Many U.S. based CROs intend to support Chinese efforts as they see benefits from these developments such as the potential for off shore clinical trials at much lower cost. China may prove to be fertile ground for clinical trials with its large population which may ease hurdles ranging from cost, patient recruitment delays, patient compliance during participation, qualified professionals, new clinical trial patients, and other problems.
"Operating pharmaceutical testing facilities and clinical trials in China will require compatible software to manage their information gathering and data mining procedures," says Chairman Gerard Dab. "Yes it is a new market and it has some challenges such as conveying novel notions like informed consent but we believe that we can leverage our Chinese experience to generate significant business in helping this budding Chinese industry."
Although health is provincial or local, the central government now allocates special budgets to hospitals for acquisition of new technology, a move that will help usher in modern clinical trials. Another critical success factor may be our proven ability to secure active support from leading academic communities, vital for both best-practice and scientific credibility.
VSHC on the move. Hearing whispers of big things coming.
VSHC is starting to run!
VSHC is starting to run!
Mornin VSHC'ers! I'm looking forward to a nice week here.
500k between us and a penny is my prediction. Any other guesses?
If it closes over .01 the trend lines broken and we can most likely expect a nice week on the horizon.
VSHC =Multi-bagger next week.
Holding around 6 nicely. Unless they hideously dilute this it won't get much cheaper folks.